# Session: sub_49c4f5c9:us_fda2

- **subagent_id**: `sub_49c4f5c9`
- **subagent_name**: `regulatory-reviewer`
- **session_id**: `us_fda2`
- **model_key**: `llm`
- **model_id**: `gemma-4-31b-it`
- **provider**: `openai_compat`
- **tools_granted**: `["Read", "Write", "Glob", "Grep"]`
- **accessible_paths**: `["/playpen2/xkaiwen/smbench_results/exp/local-qwen3.6-27b/run_local2_2780990/run_1780830995_516fc2/s_clinical_trial_protocol/work/regulations", "/playpen2/xkaiwen/smbench_results/exp/local-qwen3.6-27b/run_local2_2780990/run_1780830995_516fc2/s_clinical_trial_protocol/work/protocols/v3_amendments.md", "/playpen2/xkaiwen/smbench_results/exp/local-qwen3.6-27b/run_local2_2780990/run_1780830995_516fc2/…[truncated 39 chars]`
- **context_size_max**: `62378`

## System Prompt

```
You are a medical affairs regulatory specialist reviewing clinical trial documents. Your task: read all three regulatory PDFs (cn_nmpa_2026.pdf, eu_ema_2026.pdf, us_fda_2026.pdf) in the regulations directory, and combine with the recruitment breakdown from the v3 amendments file. Produce a concise regulatory_map.md with: (1) study recruitment breakdown by country, (2) at least one key compliance requirement per country (CN, DE, US), citing exact section/clause numbers from the source PDFs. Output to notes/regulatory_map.md in the output directory. Be terse — plain bullets, no fluff.
```

## Timeline

## Turn 1 — user
Read ONLY the first 300 lines of regulations/us_fda_2026.pdf. Extract at least one key compliance requirement for a Phase II clinical trial, citing exact section/clause numbers. Return just 2 bullet points max.

> _system-reminder_: Context usage: 2212/100000 tokens (2%).

## Turn 2 — assistant
### Tool Call: `Read`
- **file_path**: `regulations/us_fda_2026.pdf`
- **limit**: `300`

## Turn 3 — tool_result
_tool_call_id_: `chatcmpl-tool-b3354c535c72de9e`

tool error: file_path must be an absolute path; got 'regulations/us_fda_2026.pdf'. Use a path under one of your accessible roots.

## Turn 4 — assistant
### Tool Call: `Glob`
- **pattern**: `**/us_fda_2026.pdf`

## Turn 5 — tool_result
_tool_call_id_: `chatcmpl-tool-9ac3440030a92188`

/playpen2/xkaiwen/smbench_results/exp/local-qwen3.6-27b/run_local2_2780990/run_1780830995_516fc2/s_clinical_trial_protocol/work/regulations/us_fda_2026.pdf

## Turn 6 — assistant
### Tool Call: `Read`
- **file_path**: `/playpen2/xkaiwen/smbench_results/exp/local-qwen3.6-27b/run_local2_2780990/run_1780830995_516fc2/s_clinical_trial_protocol/work/regulations/us_fda_2026.pdf`
- **limit**: `300`

## Turn 7 — tool_result
_tool_call_id_: `chatcmpl-tool-bc3429754eabf6a9`

1	--- Page 1 ---
2	U.S. Food and Drug Administration (FDA)
3	21 CFR Part 312 — Investigational New Drug Application (IND)
4	Incorporating ICH E6(R3) Good Clinical Practice Guidelines
5	Revised: 2026-02-01
6	SUBPART A — GENERAL PROVISIONS
7	Applicable to IND TR-2026-PHII-091-IND-4821 for compound-X42…[truncated 302600 chars]

> _system-reminder_: You have just crossed the 50% threshold of your context window (62178/100000 tokens). Consolidate context, summarise long subagent transcripts in your own words, and avoid redundant exploration.

> _system-reminder_: You have just crossed the 60% threshold of your context window (62178/100000 tokens). Consolidate context, summarise long subagent transcripts in your own words, and avoid redundant exploration.

## Turn 8 — assistant
**content**:

* Maintain complete and accurate records throughout the trial lifecycle, with retention for at least 15 years following trial completion or regulatory submission (FDA-US-B.001).
* Implement Central Statistical Monitoring (CSM) for all critical data points, including primary endpoints, safety laborat…[truncated 43 chars]
